Author response for "Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase‐4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: a subgroup analysis of the randomized CAROLINA trial"
2020 ◽
2020 ◽
2020 ◽
2020 ◽
2020 ◽
2020 ◽
2020 ◽
Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase‐4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized
CAROLINA
trial
2020 ◽
2020 ◽
